Autopsy report · NCT05421936

Osimertinib for NSCLC With Uncommon EGFR Mutations

“Result summarized and published”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 6 months after it had already started.
• Suspended: paused, and may or may not restart.
• 100 participants planned (an estimate, not an actual count).

Vital statistics

Status

Suspended

Sponsor

Sheba Medical Center

Sponsor type

Government (non-US federal)

Conditions

Carcinoma, Non-Small-Cell Lung; Genes, erbB-1

Interventions

Osimertinib

Participants

100 (planned, not actual)

Sites

1

Countries

Israel

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.